康方生物-B(09926)发布PD-1/VEGF双抗Ia期研究初步数据：对PD-1不敏感型实体瘤患者效果良好
© Reuters. 康方生物-B(09926)发布PD-1/VEGF双抗Ia期研究初步数据：对PD-1不敏感型实体瘤患者效果良好
智通财经APP获悉，11月2日在北京举办的2020中国肿瘤免疫治疗会议上，康方生物-B(09926)发布了其自主研发的PD-1/VEGF双特异性抗体（AK112）最新的Ia期剂量爬坡临床研究初步数据，研究显示AK112针对PD-1不敏感型实体瘤患者效果良好。
据悉，目前PD-1抗体与VEGF阻断剂的联合疗法已在多种瘤种（如肾细胞癌、非小细胞肺癌和肝细胞癌）中显示出良好的疗效。PD-1/VEGF双抗（AK112）是康方生物第二款进入临床的双特异性抗体，也是全球首个进入临床研究的PD-1/VEGF双抗。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.